• Publications
  • Influence
The product of the imprinted H19 gene is an oncofetal RNA.
The H19 gene is expressed in tumours arising from tissues which express this gene in fetal life, and its expression in the fetus and in cancer is closely linked with tissue differentiation. Expand
Genomic imprinting and the endometrial cycle. The expression of the imprinted gene H19 in the human female reproductive organs.
The expression of H19 was examined by in situ hybridization applied to paraffin sections of human endometrium and ovaries at different stages of differentiation and an association between H19 expression during the menstrual cycle and the differentiation state of the human female reproductive tract, which is under hormonal control, is suggested. Expand
Imprinted H19 oncofetal RNA is a candidate tumour marker for hepatocellular carcinoma.
The addition of a non-radioactive in situ hybridisation assay for H19 RNA to the panel of tumour markers used for the histopathological and cytological diagnosis of hepatocellular carcinoma might be useful. Expand
The Increasing Complexity of the Oncofetal H19 Gene Locus: Functional Dissection and Therapeutic Intervention
A DNA-based therapeutic approach uses a diphtheria toxin A (DTA) protein expressed under the regulation of the H19 promoter to treat tumors with significant expression of H19 RNA, which is currently under development. Expand
H19 in normal development and neoplasia
Parental imprinting of the human H19 gene
Using a unique human tissue, the androgenetic complete hydatidiform mole, it is established that the maternally inherited allele of the imprinted H19 gene is expressed and that the paternal allele ofthe human IGF‐II gene, a gene suspected to be parentally imprinted in humans, is expressed. Expand
The expression of the imprinted H19 and IGF‐2 genes in human bladder carcinoma
Observations support the notion of a positive correlation between H19 expression and bladder carcinoma, and demonstrate that H19 RNA is an oncofetal RNA. Expand
Development of targeted therapy for ovarian cancer mediated by a plasmid expressing diphtheria toxin under the control of H19 regulatory sequences
A new therapy strategy to target the expression of diphtheria toxin gene under the control of H19 regulatory sequences in ovarian tumor cells is developed to identify likely non-responders in advance and to treat patients who are resistant to all known therapies, thereby avoiding treatment failure. Expand
Relaxation of imprinting in trophoblastic disease.
It is suggested that the expression of the maternally expressed H19 gene in the androgenetic tissue of complete hydatidiform mole represents relaxation of imprinting and may be associated with its malignant potential. Expand
H19 expression in hepatic metastases from a range of human carcinomas
H19 is highly expressed in more than half of hepatic metastases derived from a range of carcinomas, thus, these metastases may be suitable candidates for H19 DNA based treatment. Expand